Skip to main content

Table 4 Multivariate analysis by adjusted age, sex and T category or N category of the two editions

From: Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era

 

OS

LRRFS

DFS

7th edition

 T category

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

 T1 vs. T2

1.465 (0.350–6.133)

0.601

1.114 (0.352–3.525)

0.855

1.183 (0.450–3.111)

0.733

 T1 vs. T3

0.559 (0.178–1.715)

0.318

1.513 (0.383–5.975)

0.554

0.614 (0.269–1.399)

0.245

 T1 vs. T4

0.212 (0.081–0.558)

0.020

1.583 (0.456–5.502)

0.470

0.305 (0.149–0.625)

0.001

 Overall P

<0.001

0.364

<0.001

8th edition

 T category

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

 T1 vs. T2

1.506 (0.360–6.307)

0.575

1.190 (0.376–3.768)

0.767

1.075 (0.424–2.726)

0.878

 T1 vs. T3

0.343 (0.130–0.908)

0.031

1.470 (0.510–4.238)

0.476

0.487 (0.239–0.996)

0.049

 T1 vs. T4

0.194 (0.065–0.580)

0.003

0.310 (0.030–3.203)

0.326

0.239 (0.100–0.572)

0.001

 Overall P

<0.001

0.144

<0.001

 

OS

DMFS

DFS

7th edition

 N category

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

 N1 vs. N0

0.104 (0.013–0.805)

0.300

0.781 (0.138–4.410)

0.779

0.137 (0.032–0.595)

0.008

 N1 vs. N2

0.862 (0.427–1.743)

0.680

0.580 (0.184–1.823)

0.351

0.944 (0.533–1.671)

0.842

 N1 vs. N3a

1.632 (0.210–12.690)

0.640

0.216 (0.037–1.265)

0.089

0.747 (0.218–2.566)

0.643

 N1 vs. N3b

0.587 (0.188–1.836)

0.360

0.371 (0.066–2.089)

0.261

0.514 (0.215–1.231)

0.135

 Overall P

0.004

0.519

<0.001

8th edition

 N category

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

 N1 vs. N0

2.095 (1.270–3.457)

0.004

1.722 (0.701–4.231)

0.236

1.700 (0.746–3.877)

<0.001

 N1 vs. N2

1.212 (0.592–1.212)

0.599

1.985 (0.629–6.264)

0.242

1.098 (0.612–1.970)

0.754

 N1 vs. N3

1.037 (0.649–1.656)

0.880

1.408 (0.701–2.829)

0.337

1.166 (0.818–1.662)

0.395

 Overall P

0.008

0.316

0.001

  1. Abbreviations: CI Confidence interval. HR Hazard ratio. OS Overall survival. DFS Disease-free survival. LRRFS Locoregional recurrence-free survival. DMFS Distant metastasis-free survival